{"id":"W4293565846","doi":"10.1016/j.jtocrr.2022.100400","title":"BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre; Alberta Health Services; McMaster University; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; University of Alberta","funders":"Genentech; Astellas Pharma; Regeneron Pharmaceuticals; Ipsen; BeiGene; Merck KGaA; Daiichi Sankyo Europe; Sanofi; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Adverse effect; Combination therapy; Internal medicine; Pharmacokinetics; Refractory (planetary science); Oncology; Confidence interval; Progression-free survival; Phases of clinical research; Clinical endpoint; Gastroenterology; Pharmacology; Chemotherapy; Immunotherapy; Cancer; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008268111,0.0002102078,0.0004308594,0.000473719,0.0003516806,0.00008906345,0.0002871446,0.0002180243,0.0001802329],"category_scores_gemma":[0.001454477,0.0001703277,0.00006432593,0.0007231348,0.0002993945,0.00002859707,0.0003846963,0.00131197,0.000002879427],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008825702,"about_ca_system_score_gemma":0.0006322899,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00628608,"about_ca_topic_score_gemma":0.011761,"domain_scores_codex":[0.993967,0.001671916,0.00125451,0.001244957,0.001298525,0.0005631001],"domain_scores_gemma":[0.9982005,0.0002779054,0.0002207722,0.0007701899,0.000262437,0.000268149],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02470527,0.02297845,0.9060702,0.00002728444,0.00007945799,0.009177971,0.001086915,0.0002771115,0.02351966,0.00001622273,0.0005559929,0.01150548],"study_design_scores_gemma":[0.04838417,0.03522914,0.8817083,0.0001046962,0.000008059946,0.0001005702,0.002754215,0.00195281,0.002693394,0.0008152293,0.02566057,0.0005888821],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970149,0.0002109566,0.000005281637,0.0005793556,0.00007714691,0.001709501,0.00003372083,0.0000129415,0.0003561337],"genre_scores_gemma":[0.9975642,0.0003015524,0.00006827898,0.00006452186,0.0001068722,0.0002543548,0.0004478668,0.00003523862,0.001157094],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02510457,"threshold_uncertainty_score":0.9502715,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07985497471285384,"score_gpt":0.466754628081248,"score_spread":0.3868996533683942,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}